× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Findings

What does this study add?

  • Of subjects who received rimegepant 75 mg, 20.1% reported freedom from pain 2 hours post-dose versus 12.2% who received placebo.
  • 36.4% of subjects who took rimegepant 75 mg reported freedom from MBS 2 hours post-dose versus 26.6% who received placebo.
  • Rimegepant 75 mg provided pain relief (defined as pain of mild intensity or none) at 2 hours post-dose for 57.9% of subjects versus 43.9% for placebo, and for up to 48 hours in 37.8% of subjects versus 24.0% on placebo.
  • Sustained normal function from 2 to 48 hours post-dose was reported by 22.3% of subjects on  rimegepant 75 mg versus 13.7% on placebo.
  • Rimegepant 75 mg was well tolerated, with the most common AEs being nausea and UTI.